Joseph S. Zakrzewski - 17 Jun 2021 Form 3 Insider Report for Cyteir Therapeutics, Inc.

Role
Director
Signature
By: /s/ Andrew Gengos, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
17 Jun 2021
Net transactions value
$0
Form type
3
Filing time
17 Jun 2021, 21:43:58 UTC
Previous filing
16 Jun 2021
Next filing
24 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CYT Common Stock 77,267 17 Jun 2021 Direct F1
holding CYT Common Stock 149,051 17 Jun 2021 See Footnote F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CYT Series B Convertible Preferred Stock 17 Jun 2021 Common Stock 58,671 See Footnote F3, F4
holding CYT Stock Option (Right to Buy) 17 Jun 2021 Common Stock 97,209 $7.09 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 115,208 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option, and are subject to forfeiture until they vest.
F2 Held by Z3 Trust, of which the Reporting Person is a Trustee. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein.
F3 The shares of Series B Convertible Preferred Stock are convertible into the number of shares of the Issuer's common stock shown in column 3 and have no expiration date. The Series B Convertible Preferred Stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.
F4 Held by Z Investments, LLC, of which the Reporting Person is the Managing Director. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein.
F5 The option is exercisable as to 1/36th of the underlying shares of common stock at the end of each successive one-month period following the vesting commencement date, February 5, 2021, until the option is fully vested on the third anniversary of such date, subject to the Reporting Person's continued service on the Issuer's board of directors through the applicable vesting date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney